DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Cerebral (Fatal) Malaria - Pipeline Review, H2 2016" report to their offering.
Cerebral malaria is the most dangerous and life-threatening form of malaria that affects the brain. It is caused by plasmodium falciparum, a protozoan parasite. Plasmodium gets transmitted to human via infected mosquito bites. Symptoms include fever, head ache, muscle pain, low blood pressure, coma and convulsions. Treatment includes antimalarial, antiseizure and anti inflammatory medications.
This report provides comprehensive information on the therapeutic development for Cerebral malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cerebral malaria and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
- Callaghan Innovation Research Ltd
- Eisai Co Ltd
- Lipocure Ltd
Key Topics Covered:
- Cerebral malaria Overview
- Therapeutics Development
- Pipeline Products for Cerebral malaria - Overview
- Pipeline Products for Cerebral malaria - Comparative Analysis
- Cerebral malaria - Therapeutics under Development by Companies
- Cerebral malaria - Therapeutics under Investigation by Universities/Institutes
- Cerebral malaria - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Cerebral malaria - Products under Development by Companies
- Cerebral malaria - Products under Investigation by Universities/Institutes
- Cerebral malaria - Companies Involved in Therapeutics Development
For more information about this report visit http://www.researchandmarkets.com/research/dbtnjl/cerebral_fatal